Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WASHINGTON, Aug. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Provides Update on Tradipitant Development Program

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) took another big step forward in the fight against COVID-19 on Tuesday morning.

Vanda Pharma’s Big Step Forward in COVID-19 Pneumonia

WASHINGTON, Aug. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia

Vanda Pharmaceuticals Is Still Undervalued Despite Strong Performance During The Pandemic

Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2020 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates

WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome

WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.

Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)---- $VNDA #ClassAction--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934.

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.

FDA Grants Extra Access to Vanda's Tradipitant to a Patient

WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303). This patient had previously...

FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis

Genmab - ADR

iShares Nasdaq Biotechnology ETF

Innoviva

Novavax

Trillium Therapeutics

Vertex Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Top Biotech Stocks for Q3 2020

Vanda Pharmaceuticals (NASDAQ: VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

Why Vanda's Stock Is Trading Lower Today

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company. On May 19, 2020, Judge Amit P. Mehta...

Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery...

Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

No matter how much courage an investor has, investing in cheap stocks that have pending whistleblower lawsuits against them just isn't a good idea.

1 Pharma Stock to Avoid at All Costs

Third-quarter results from a COVID-19 trial could send this stock soaring.

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2020 Results - Earnings Call Transcript

Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates

Vanda Pharmaceuticals: Undervalued Despite Its COVID-19 Treatment Potential

Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.

Vanda Begins Enrollment in Study for Severe Coronavirus Infection

Vanda Pharmaceuticals' (VNDA) CEO Mihales Polymeropoulos on Q4 2019 Results - Earnings Call Transcript

First Horizon National

Janus Henderson Group

PG&E

Principal Financial Group

THL Credit

A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.

7 Stocks With Low Price-to-Sales Ratio for a Solid Portfolio

Vanda Loses Against The FDA, And Other News: The Good, Bad, And Ugly Of Biopharma

News for Vanda Pharmaceuticals Stock (VNDA)